Goldman Sachs Upgrades PerkinElmer and Affy, Downgrades Thermo Fisher | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded PerkinElmer and Affymetrix but downgraded Thermo Fisher Scientific.

In a report outlining its outlook for 2012 in the broad medical technology space, analysts Isaac Ro and David Roman upgraded the investment firm's rating for PerkinElmer to Buy from Neutral, saying changes it has made in recent years has left it well positioned in the coming year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.